Mar 30, 2023 4:30pm EDT Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
Mar 17, 2023 4:01pm EDT Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 17, 2023 4:01pm EST Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 09, 2023 4:05pm EST Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Jan 04, 2023 8:00am EST Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 21, 2022 8:00am EST Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
Dec 20, 2022 4:05pm EST Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Dec 10, 2022 10:30am EST Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
